Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-12-15 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
天衡会计师事务所(特殊普通合伙)关于金陵药业股份有限公司申请向特定对象发行股票的审核问询函的回复
Interim / Quarterly Report Classification · 95% confidence The document is a detailed response to an inquiry letter regarding a company's application for a specific share issuance. It contains extensive financial data, including audited financial statements for 2020, 2021, and 2022, detailed analysis of revenue, profit, cost structures, and comparisons with industry peers. The document includes financial tables, explanations of business segments, and discussion of financial performance trends over multiple years and interim periods (e.g., 2023 1-9 months). The presence of detailed financial statements and substantive financial data indicates this is a comprehensive financial report rather than a brief announcement or certification. The document is not a transcript, proxy, or governance report, but a thorough financial and operational analysis typically found in an Interim / Quarterly Report or Annual Report. Since it covers multiple years and interim periods but is not a full annual report, and given the detailed financial data for 2023 1-9 months, it aligns best with an Interim / Quarterly Report (IR). 9M 2023
2023-12-15 Chinese
金陵药业股份有限公司2023年度向特定对象发行A股股票募集说明书（注册稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书（注册稿）" which translates to "Prospectus (Registration Draft)" for a specific issuance of A shares by Jinling Pharmaceutical Company Limited in 2023. It contains detailed information about the company's fundraising plan, risk factors related to the issuance, project descriptions, financial impacts, and other disclosures related to the capital raising. The document is lengthy (15,000 characters) and contains substantive financial and operational details about the fundraising projects and their expected impact on the company. This matches the characteristics of a Capital/Financing Update, which includes updates on company fundraising and financing activities. It is not an Annual Report, Earnings Release, or other report types. It is also not a simple announcement or a regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-12-15 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2023年度向特定对象发行A股股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) for Jinling Pharmaceutical Company's 2023 private placement of A shares. It is issued by CITIC Securities as the sponsor. The content includes detailed information about the securities issuance, the sponsor's responsibilities, legal and regulatory compliance, the issuer's background, shareholding structure, financial data, and the sponsor's recommendation for the issuance. It discusses the issuance type, approval procedures, compliance with laws and regulations, and the use of proceeds. This document is a formal sponsorship letter related to a capital raising event (private placement of shares). It is not a full annual report, earnings release, or other financial report. It is not a simple announcement or a proxy statement. It is a detailed document related to a capital/financing update, specifically the issuance of new shares to specific investors. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-12-15 Chinese
金陵药业股份有限公司关于向特定对象发行股票的审核中心意见落实函回复及募集说明书等申请文件更新的提示性公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the response to the Shenzhen Stock Exchange's review comments on the company's application for a private placement of shares. It mentions updates and revisions to the prospectus and related application documents, and notes that the issuance is subject to approval by the China Securities Regulatory Commission. The document is relatively short (906 characters) and primarily serves as a notice about the status and updates of the private placement application, rather than containing the full prospectus or detailed financial data. Therefore, it is an announcement related to capital raising activities but not the full financing report itself. According to the classification rules, such updates on fundraising and capital structure changes fall under Capital/Financing Update (CAP).
2023-12-14 Chinese
关于金陵药业股份有限公司申请向特定对象发行股票的审核问询函之回复报告
Capital/Financing Update Classification · 95% confidence The document is a detailed reply report to a review inquiry letter from the Shenzhen Stock Exchange regarding a company's application for a private placement of shares. It contains extensive financial data, business analysis, market position, product pricing, cost trends, and comparisons with industry peers. The content is focused on financial performance, operational details, and regulatory compliance related to a capital raising process. This type of document is characteristic of a Capital/Financing Update (CAP) filing, as it pertains to the company's financing activities and includes detailed financial and operational disclosures to support the issuance of new shares to specific investors. It is not an annual or interim report, nor a simple announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-12-14 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2023年度向特定对象发行A股股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) for Jinling Pharmaceutical Company's 2023 private placement of A shares. It is issued by CITIC Securities as the sponsor and underwriter. The content includes detailed information about the securities issuance, the sponsor's responsibilities, legal and regulatory compliance, the issuer's background, shareholding structure, financial data, and the sponsor's internal review and opinions. The document is a formal sponsorship letter related to a capital raising event (private placement of shares). It is not a general annual report, earnings release, or management discussion, but specifically a detailed document supporting and recommending the issuance of new shares to specific investors. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length (15,000 characters) and detailed content confirm it is the actual sponsorship document, not just an announcement or summary. Therefore, the correct classification is CAP with high confidence.
2023-12-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.